Benjamin Bakall

1 month ago | healio.com | Benjamin Bakall |Alex Young |Eamon Dreisbach |Anthony DeFino

SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Benjamin Bakall, MD, PhD, discusses 2-year data from the TEASE-1 study investigating the safety and efficacy of gildeuretinol in patients with Stargardt disease. The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a significant reduction in growth of the area of atrophy.